[go: up one dir, main page]

PE20080331A1 - Composiciones farmaceuticas estabilizadas que comprenden fesoterodina - Google Patents

Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Info

Publication number
PE20080331A1
PE20080331A1 PE2007000695A PE2007000695A PE20080331A1 PE 20080331 A1 PE20080331 A1 PE 20080331A1 PE 2007000695 A PE2007000695 A PE 2007000695A PE 2007000695 A PE2007000695 A PE 2007000695A PE 20080331 A1 PE20080331 A1 PE 20080331A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
compositions including
fesoterodine
stabilized pharmaceutical
composition
Prior art date
Application number
PE2007000695A
Other languages
English (en)
Inventor
Christoph Arth
Han-Jurgen Mika
Michael Komenda
Kerstin Paulus
Hans Lindner
Fatima Bicane
Meike Irngartinger
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080331(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of PE20080331A1 publication Critical patent/PE20080331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE FESOTERODINA Y UN ESTABILIZANTE SELECCIONADO ENTRE XILITOL, SORBITOL, POLIDEXTROSA, ISOMALTA, ENTRE OTROS, DONDE LA RELACION FESOTERODINA/ESTABILIZANTE ES 1%-20%p/p. LA COMPOSICION ES OBTENIDA A TRAVES DE UN METODO DE GRANULACION HUMEDA Y TIENE COMO AGENTES DE LIBERACION RETARDADA AL ETER O ESTER DE CELULOSA O HIDROXIPROPILMETILCELULOSA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE DISFUNCIONES DEL TRACTO URINARIO, COMO VEJIGA HIPERACTIVA E INCONTINENCIA URINARIA
PE2007000695A 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina PE20080331A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011943 2006-06-09
EP06011941 2006-06-09

Publications (1)

Publication Number Publication Date
PE20080331A1 true PE20080331A1 (es) 2008-06-19

Family

ID=38521333

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001996A PE20120476A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
PE2007000695A PE20080331A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001996A PE20120476A1 (es) 2006-06-09 2007-06-06 Composiciones farmaceuticas estabilizadas que comprenden fesoterodina

Country Status (37)

Country Link
EP (1) EP2029134B1 (es)
JP (2) JP4743321B2 (es)
KR (1) KR101316773B1 (es)
CN (1) CN101466371B (es)
AP (1) AP2416A (es)
AR (1) AR061289A1 (es)
AT (1) ATE517619T1 (es)
AU (1) AU2007255408B2 (es)
BR (1) BRPI0712865B1 (es)
CA (1) CA2652712C (es)
CR (1) CR10494A (es)
CU (1) CU23850B1 (es)
CY (1) CY1111934T1 (es)
DK (1) DK2029134T3 (es)
EA (1) EA015909B9 (es)
EC (1) ECSP089010A (es)
ES (1) ES2370943T3 (es)
GT (1) GT200800276A (es)
HR (1) HRP20110776T1 (es)
IL (2) IL195732A (es)
MA (1) MA30504B1 (es)
MX (1) MX2008015736A (es)
MY (1) MY146574A (es)
NI (1) NI200800318A (es)
NL (1) NL2000690C2 (es)
NO (1) NO341980B1 (es)
NZ (1) NZ572616A (es)
PE (2) PE20120476A1 (es)
PL (1) PL2029134T3 (es)
PT (1) PT2029134E (es)
RS (1) RS51973B (es)
SI (1) SI2029134T1 (es)
TN (1) TNSN08505A1 (es)
TW (2) TWI520735B (es)
UY (1) UY30394A1 (es)
WO (1) WO2007141298A1 (es)
ZA (1) ZA200806411B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
CA2761602C (en) 2009-05-11 2015-07-07 Ratiopharm Gmbh Desfesoterodine in the form of a tartaric acid salt
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
EP2867199B1 (en) * 2012-07-02 2018-04-18 Hetero Research Foundation Stable compositions of fesoterodine
DK2914255T3 (da) 2012-11-02 2021-10-25 Murray & Poole Entpr Ltd Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
CA3094551C (en) 2018-04-26 2024-01-02 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
CA3187827A1 (en) * 2020-06-30 2022-01-06 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
WO2023145486A1 (ja) * 2022-01-28 2023-08-03 沢井製薬株式会社 フェソテロジンフマル酸塩含有製剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ506578A (en) * 1998-03-03 2003-09-26 Shionogi & Co Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)- 2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
AU2007255408A1 (en) 2007-12-13
JP2009539802A (ja) 2009-11-19
JP4743321B2 (ja) 2011-08-10
NZ572616A (en) 2010-11-26
PL2029134T3 (pl) 2011-12-30
UY30394A1 (es) 2007-11-30
GT200800276A (es) 2009-06-18
PE20120476A1 (es) 2012-04-20
TW201336491A (zh) 2013-09-16
NO341980B1 (no) 2018-03-05
ES2370943T3 (es) 2011-12-23
EP2029134A1 (en) 2009-03-04
IL195732A (en) 2013-09-30
JP4781489B2 (ja) 2011-09-28
EA015909B9 (ru) 2012-03-30
IL195732A0 (en) 2009-09-01
ATE517619T1 (de) 2011-08-15
AP2416A (en) 2012-06-01
JP2011140498A (ja) 2011-07-21
HK1128626A1 (en) 2009-11-06
CA2652712A1 (en) 2007-12-13
ZA200806411B (en) 2009-05-27
CY1111934T1 (el) 2015-11-04
IL220800A (en) 2015-03-31
KR101316773B1 (ko) 2013-10-15
BRPI0712865B1 (pt) 2021-08-17
CN101466371A (zh) 2009-06-24
AP2008004673A0 (en) 2008-12-31
TNSN08505A1 (fr) 2010-04-14
AU2007255408B2 (en) 2013-03-14
NI200800318A (es) 2011-01-12
TW200814992A (en) 2008-04-01
NL2000690A1 (nl) 2007-12-11
EA015909B1 (ru) 2011-12-30
CU20080235A7 (es) 2011-04-26
MY146574A (en) 2012-08-30
CU23850B1 (es) 2012-10-15
ECSP089010A (es) 2009-01-30
HRP20110776T1 (hr) 2011-11-30
NO20090141L (no) 2009-01-09
CN101466371B (zh) 2011-10-05
MA30504B1 (fr) 2009-06-01
NL2000690C2 (nl) 2008-04-01
CR10494A (es) 2009-01-19
WO2007141298A1 (en) 2007-12-13
BRPI0712865A2 (pt) 2012-12-18
SI2029134T1 (sl) 2012-01-31
AR061289A1 (es) 2008-08-20
EP2029134B1 (en) 2011-07-27
TWI397409B (zh) 2013-06-01
RS51973B (sr) 2012-02-29
DK2029134T3 (da) 2011-10-17
KR20090026135A (ko) 2009-03-11
MX2008015736A (es) 2009-01-09
EA200802444A1 (ru) 2009-06-30
CA2652712C (en) 2014-04-01
TWI520735B (zh) 2016-02-11
PT2029134E (pt) 2011-11-02

Similar Documents

Publication Publication Date Title
PE20080331A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
BRPI0710485A8 (pt) composições e métodos úteis para tratamento de doenças respiratórias
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
DOP2009000135A (es) Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituídos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
PE20090951A1 (es) Suspension pediatrica estabilizada de carisbamato
CL2007002818A1 (es) Procedimiento para combatir plagas animales u hongos fitopatogenos; composicion agroquimica para la aplicacion en el suelo que contiene al menos un principio activo agroquimico y un adyuvante; uso del adyuvante para preparar composiciones agroquimica
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
GT200600097A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
EP1968566A4 (en) COMPOSITIONS OF CIS-9, TRANS-11 CONJUGATED LINOLIC ACID AND VACCENIC ACID AND ITS USES

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FG Grant, registration